Literature DB >> 19812565

Gateway to the diseased brain.

Federico Mingozzi, Katherine A High.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19812565     DOI： 10.1038/nm1009-1123

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  11 in total

Review 1.  Molecular engineering of viral gene delivery vehicles.

Authors:  David V Schaffer; James T Koerber; Kwang-il Lim
Journal:  Annu Rev Biomed Eng       Date:  2008       Impact factor: 9.590

2.  Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virus-based vectors.

Authors:  Andrew I Brooks; Colleen S Stein; Stephanie M Hughes; Jason Heth; Paul M McCray; Sybille L Sauter; Julie C Johnston; Deborah A Cory-Slechta; Howard J Federoff; Beverly L Davidson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-16       Impact factor: 11.205

3.  Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2.

Authors:  A Girod; M Ried; C Wobus; H Lahm; K Leike; J Kleinschmidt; G Deléage; M Hallek
Journal:  Nat Med       Date:  1999-09       Impact factor: 53.440

Review 4.  Treating lysosomal storage disorders: current practice and future prospects.

Authors:  Frances M Platt; Robin H Lachmann
Journal:  Biochim Biophys Acta       Date:  2008-09-05

5.  VEGF disrupts the neonatal blood-brain barrier and increases life span after non-ablative BMT in a murine model of congenital neurodegeneration caused by a lysosomal enzyme deficiency.

Authors:  Pampee P Young; Corinne R Fantz; Mark S Sands
Journal:  Exp Neurol       Date:  2004-07       Impact factor: 5.330

6.  Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes.

Authors:  Kevin D Foust; Emily Nurre; Chrystal L Montgomery; Anna Hernandez; Curtis M Chan; Brian K Kaspar
Journal:  Nat Biotechnol       Date:  2008-12-21       Impact factor: 54.908

7.  A single injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease.

Authors:  Cassia N Cearley; John H Wolfe
Journal:  J Neurosci       Date:  2007-09-12       Impact factor: 6.167

8.  Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy.

Authors:  Guang-Ping Gao; Mauricio R Alvira; Lili Wang; Roberto Calcedo; Julie Johnston; James M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-21       Impact factor: 11.205

9.  Vascular bed-targeted in vivo gene delivery using tropism-modified adeno-associated viruses.

Authors:  Lorraine M Work; Hildegard Büning; Ela Hunt; Stuart A Nicklin; Laura Denby; Nicola Britton; Kristen Leike; Margarete Odenthal; Uta Drebber; Michael Hallek; Andrew H Baker
Journal:  Mol Ther       Date:  2006-01-04       Impact factor: 11.454

10.  Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy.

Authors:  Yong Hong Chen; Michael Chang; Beverly L Davidson
Journal:  Nat Med       Date:  2009-09-13       Impact factor: 53.440
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.